Discussing the future Multiple Myeloma treatment landscape following multiple datasets presented at ASH 2025 including Iberdomide, CARVYKTI, and anito-cel from Bristol Myers, JNJ & Gilead

Executed on:Jan 15, 2026 5:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Fred Hutchinson Cancer Research Center & Univ. of WashingtonHematologist and Medical Oncologist at Fred Hutch & Associate Professor, Department of Medical Oncology.
Treats 20-30 cases of refractory gastrointestinal acute graft-versus-host disease per year, 100 patients with CLL and 60 patients with r/r DLBCL.
Research focuses on improving outcome for patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease using autologous transplant techniques.

Interview Goal

This call will feature a discussion on the current treatment landscape for multiple myeloma including the data which was presented at ASH 2025 on several candidates. The drugs of focus include BMS' Iberdomide, Johnson & Johnson' CARVYKTI (ciltacabtagene autoleucel; cilta-cel), and Gilead's anitocabtagene autoleucel (anito-cel).

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.